ARTICLE | Product Development
Arcus data the latest twist in the TIGIT story
BioCentury’s Clinical Report also analyzes the impact of a patient death in Beam’s trial, plus data from Cogent, Disc, Essa and Novo
November 5, 2024 11:50 PM UTC
The TIGIT rollercoaster takes another turn, with overall survival data from a small study of Arcus’ domvanalimab that could swing sentiment in a positive direction, if slightly.
Arcus Biosciences Inc. (NYSE:RCUS) reported, ahead of a presentation at the Society for Immunotherapy of Cancer (SITC) conference this week, that domvanalimab plus PD-1 inhibitor zimberelimab reduced the risk of death by 36% when used as first-line therapy in patients with PD-L1-high non-small cell lung cancer (NSCLC) over zimberelimab alone...
BCIQ Company Profiles